Which patients with desmoid tumors is observation appropriate for?
When do you decide to move to surgery, pharmacotherapies, or other modalities in these patients

Related Content

City St. George’s researcher Ateequllah Hayat, PhD, explains newly identified mechanisms behind lapatinib resistance in HER2-positive breast cancer.

New Molecular Drivers of HER2 Breast Cancer Resistance: A Q&A With Ateequllah Hayat, PhD

February 4th 2026

Article

Ateequllah Hayat, PhD, discusses epigenetic rewiring, biomarkers, and emerging strategies to overcome lapatinib resistance in HER2+ breast cancer.

Switching From MA to TM Increases Mental Health Care Use: Angela Liu, PhD, MPH

December 23rd 2025

Podcast

Angela Liu, PhD, MPH, speaks about her study that examined mental health care use by Medicare beneficiaries before and after switching from MA to TM.

Listen

A Lancet Respiratory Medicine study links telomere shortening and polygenic risk to distinct genetic endotypes in IPF. | Image Credit: lucadp-Adobestockjpeg

Telomere Length and Polygenic Risk Shape Endotypes in Idiopathic Pulmonary Fibrosis

February 3rd 2026

Article

Telomere length and polygenic risk independently influence IPF susceptibility, even among patients without rare genetic variants.

Managed Care Cast Presents: New Evidence and Economic Considerations in IPF Care

November 25th 2025

Podcast

Experts discuss the clinical and economic burden of idiopathic pulmonary fibrosis (IPF), emerging clinical data, and strategies to improve patient outcomes.

Listen

Glaucoma test | Image credit: Coetzee/peopleimages.com - stock.adobe.com

FAQs About Glaucoma as Awareness Month Concludes

February 2nd 2026

Article

Glaucoma is a leading cause of blindness in the US, making awareness of the condition vital to obtaining the best outcomes.

Most Patients With MCL in Study of Pirtobrutinib Show Stable or Improved Physical Symptoms, QOL

January 31st 2026

Article

Patients with mantle cell lymphoma experience improved quality of life and physical functioning after treatment with pirtobrutinib, a BTK inhibitor.

Related Content

New Molecular Drivers of HER2 Breast Cancer Resistance: A Q&A With Ateequllah Hayat, PhD

February 4th 2026

Article

Ateequllah Hayat, PhD, discusses epigenetic rewiring, biomarkers, and emerging strategies to overcome lapatinib resistance in HER2+ breast cancer.

Switching From MA to TM Increases Mental Health Care Use: Angela Liu, PhD, MPH

December 23rd 2025

Podcast

Angela Liu, PhD, MPH, speaks about her study that examined mental health care use by Medicare beneficiaries before and after switching from MA to TM.

Listen

Telomere Length and Polygenic Risk Shape Endotypes in Idiopathic Pulmonary Fibrosis

February 3rd 2026

Article

Telomere length and polygenic risk independently influence IPF susceptibility, even among patients without rare genetic variants.

Managed Care Cast Presents: New Evidence and Economic Considerations in IPF Care

November 25th 2025

Podcast

Experts discuss the clinical and economic burden of idiopathic pulmonary fibrosis (IPF), emerging clinical data, and strategies to improve patient outcomes.

Listen

FAQs About Glaucoma as Awareness Month Concludes

February 2nd 2026

Article

Glaucoma is a leading cause of blindness in the US, making awareness of the condition vital to obtaining the best outcomes.

Most Patients With MCL in Study of Pirtobrutinib Show Stable or Improved Physical Symptoms, QOL

January 31st 2026

Article

Patients with mantle cell lymphoma experience improved quality of life and physical functioning after treatment with pirtobrutinib, a BTK inhibitor.

About

Contact

Editorial Boards